Unicycive Therapeutics complies with Nasdaq listing requirement after 1:10 reverse stock split.

Unicycive Therapeutics, Inc. regains compliance with Nasdaq listing standard for minimum share price. The company’s common stock maintains an average closing share price of at least $1.00 after a 1:10 reverse stock split. Unicycive focuses on developing treatments for kidney diseases, with lead investigational treatment oxylanthanum carbonate under FDA review for hyperphosphatemia in CKD patients on dialysis. The company’s second investigational treatment, UNI-494, has received orphan drug designation from the FDA for the prevention of Delayed Graft Function in kidney transplant patients. For more information, visit Unicycive.com.

Read more at GlobeNewswire: Unicycive Therapeutics Regains Compliance with Nasdaq